Galderma Group AG, the pure-play leader in the dermatology category, announced that L’Oréal Groupe plans to increase its equity investment in the company by acquiring an additional 10 percent stake from Sunshine SwissCo GmbH, a consortium led by EQT, the Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. as the sellers.

Following this transaction, which remains subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20 percent, building on its initial investment made in August 2024. The deal is expected to close in the first quarter of 2026.

As part of the expanded investment, Galderma will consider nominating two non-independent board candidates from L’Oréal to replace the board members representing the EQT-led consortium at the 2026 Annual General Meeting.

Galderma and L’Oréal also intend to explore additional scientific research collaborations. This continued partnership brings together Galderma’s scientific strength in dermatology with L’Oréal’s global leadership in beauty. With a shared emphasis on skincare, skin health, innovation, and long-term growth, both companies are well positioned within the rapidly expanding, consumer-driven dermatology and beauty markets.

“Galderma continues to deliver impressive growth, strong innovation, and category leadership across its broad, science-based dermatology portfolio. With strengthened commercial execution, continued platform and portfolio expansion, and an increasingly consumer-focused approach to innovation, we are rapidly scaling into a dermatology powerhouse. We welcome L’Oréal’s increased investment, which reinforces our strategic direction and the significant value creation we expect in the years ahead. As we move into 2026, we remain committed to our Integrated Dermatology Strategy and to serving our customers, consumers, and patients,” said Flemming Ørnskov, M.D., MPH, chief executive officer of Galderma.

Galderma, present in around 90 countries, is recognised as the pure-play dermatology category leader. The company offers an innovative, science-based portfolio of premium flagship brands and services spanning the full spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology.